Coaxial wet-spun fibers loaded with essential oils for the treatment of chronic wounds

Catarina S. Miranda¹, Elina Marinho¹, Susana P. G. Costa², Natália C. Homem³ and Helena P. Felgueiras^{1,*}

¹Centre for Textile Science and Technology (2C2T), University of Minho, Guimarães, Portugal


²Centre of Chemistry (CQ), University of Minho, Braga, Portugal

³ Simoldes Plastics S.A., Oliveira de Azeméis, Portugal

Introduction

Chronic wounds (CWs) can greatly impact the health and quality of the (a) patients' lives. The excessive use of antibiotics has led to a significant development of antibiotic-resistant microorganisms, making it crucial to think of alternative solutions. Considering these issues, a drug delivery system made of coaxial wet-spun fibers loaded with essential oils (EOs) was proposed. Coaxial structures were produced using the wet-spinning technique, in which polycaprolactone (PCL - a synthetic polymer with excellent mechanical properties and elastic behavior) solution was loaded at the core and mixed with three EOs – Clove Oil (CO), Cinnamon Leaf Oil (CLO) and Tea Tree Oil (TTO). The shell was composed of a blend of cellulose acetate (CA - a natural polymer which has been reported to offer good structural integrity) solution, mixed with polyethylene glycol (PEG - a synthetic polymer endowed with high elasticity and porosity), so pores could be opened in the outer layer, allowing for a sustained release of the EOs loaded at the fibers' core. Physical, chemical, thermal and biological characterizations were performed. Results confirmed the potential of the engineered coaxial wet-spun fibers for wound healing applications. Still, further characterization on the fibers is necessary, including cytocompatibility tests to assure non-toxic profiles of the fibers when in contact with fibroblasts and keratinocytes.


Fibers morphology




Wet-spinning


Technique based on a non-solvent-induced phase inversion process, including a polymeric solution extrusion into a coagulation bath composed by a poor solvent or a non-solvent/solvent mixture to form a coagulating filament that will solidify as a continuous polymeric fiber. Figure 1. Microscopic observations of (a) monolayered and (b) coaxial wet-spun fibers.

Release kinetics of EOs





Coaxial wet-spun fibers



Goal of Each Microfiber Component:

CA: generate porosity and maintain fibers' structural integrity
CO/CLO/TTO: antimicrobial activity
PEG: provide elasticity to the fibers
PCL: maintain fibers' structural integrity

*MBC: Minimum Bactericidal Concentration

Produced fibers:

Figure 2. Cumulative release profile of EO-loaded wet-spun fibers. Data are reported as mean ± SD (n=3).

Antimicrobial activity




Figure 3. Percentages of inhibition of (a) *S. aureus,* (b) *S. epidermidis,* (c) *E. coli* and (d) *P. aeruginosa* bacteria in contact with all wet-spun fibers incubated in PBS for 1, 2, 4, 6 and 24 h. Data are reported as mean ± SD (n=3).

Conclusions

The potential of the engineered coaxial fibers to serve as controlled release platforms for CO/CLO/TTO was demonstrated, along with their antibacterial activity against *S. aureus, S. epidermidis, E. coli* and *P. aeruginosa*. Data confirmed the potential of this system to function as a stepwise, pH-triggered delivery platform, suitable for wound healing applications. With this investigation, a step further was taken in establishing wet-spun constructs for drug delivery in CW care.

- **CA hollow** (core: coagulation bath; shell: CA);
- CA-PEG hollow (core: coagulation bath; shell: CA combined with PEG);
- **PCL** (core: PCL; shell: coagulation bath);
- PCL-CO/CLO/TTO (core: PCL combined with CO/CLO/TTO; shell: coagulation bath);
- **PCL-CA** (core: PCL; shell: CA);
- **PCL-CO/CLO/TTO-CA** (core: PCL combined with CO/CLO/TTO; shell: CA);
- **PCL-CA-PEG** (core: PCL; shell: CA combined with PEG);
- PCL-CO/CLO/TTO-CA-PEG (core: PCL combined with CO/CLO/TTO; shell: CA combined with PEG).

Acknowledgments

This work is financed by FEDER funds through COMPETE and by national funds through FCT via the projects POCI-01-0145-FEDER-028074 (PEPTEX) and UID/CTM/00264/2019. C.S.M. acknowledges FCT for the PhD grant with reference 2020.08547.BD.



The 9th International Electronic Conference on Medicinal Chemistry

01–30 November 2023 | Online